Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Equivalence concepts in clinical trials.

V W Steinijans1, M Neuhäuser, F Bretz

  • 1Department of Biometry, Byk Gulden Pharmaceuticals, Konstanz, Germany.

European Journal of Drug Metabolism and Pharmacokinetics
|October 14, 2000
PubMed
Summary

Demonstrating superiority to placebo or active controls, or showing a dose-response, establishes efficacy. Non-inferiority trials, using clinical endpoints, assess if a new treatment is not worse than an existing one.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes.

Biometrika·2018
Same author

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).

CPT: pharmacometrics & systems pharmacology·2017
Same author

"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?

Clinical pharmacology and therapeutics·2016
Same author

[Additional classification "medicinal tumor therapy": statement by the German Society of Residents in Urology (GeSRU)].

Der Urologe. Ausg. A·2012
Same author

Simultaneous confidence bands for nonlinear regression models with application to population pharmacokinetic analyses.

Journal of biopharmaceutical statistics·2011
Same author

Assessing nonsuperiority, noninferiority, or equivalence when comparing two regression models over a restricted covariate region.

Biometrics·2009

Area of Science:

  • Clinical trial design and statistical analysis in pharmaceutical research.

Background:

  • ICH E9 Guidance emphasizes superiority trials (vs. placebo or active control) or dose-response studies for robust efficacy demonstration.
  • For serious illnesses with existing treatments, placebo-controlled trials may be unethical, necessitating active-controlled studies.
  • Active control trials include superiority and non-inferiority designs.

Purpose of the Study:

  • To explain the principles of superiority, non-inferiority, and equivalence trials in clinical research.
  • To differentiate between pharmacokinetic-based bioequivalence trials and clinical endpoint-based therapeutic equivalence/non-inferiority trials.
  • To highlight the correct statistical interpretation of non-inferiority and equivalence conclusions.

Main Methods:

  • Discussion of statistical principles for clinical trials as per ICH E9 guidance.
  • Comparison of trial designs: superiority, non-inferiority, and bioequivalence.
  • Emphasis on clinical endpoints for therapeutic equivalence and non-inferiority trials, often using parallel group comparisons.

Main Results:

  • Efficacy is best proven by superiority to placebo, active control, or demonstrating dose-response.
  • Non-inferiority trials assess if an investigational product is not worse than an active comparator using clinical endpoints.
  • Superiority over the reference treatment can be tested post-non-inferiority confirmation without significance level adjustment.

Conclusions:

  • Non-inferiority and equivalence conclusions rely on confidence intervals within acceptance ranges, not non-significant difference tests.
  • Active control trials are crucial when placebo controls are unethical.
  • Proper statistical interpretation is vital for valid non-inferiority and equivalence claims in clinical research.

Related Experiment Videos